

Does magnesium augment the pain relieving effects of low dose intravenous lidocaine (lignocaine) in patients with chronic non malignant pain? A randomised double-blind crossover study

Submission date 30/09/2004	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2004	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 22/04/2015	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr A P Baranowski

Contact details
Pain Management Department
National Hospital for Neurology & Neurosurgery
Queen Square
London
United Kingdom
WC1N 3BG

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0263139706

Study information

Scientific Title

Does magnesium augment the pain relieving effects of low dose intravenous lidocaine (lignocaine) in patients with chronic non malignant pain? A randomised double-blind crossover study

Study objectives

Can the addition of magnesium sulphate to systemic low dose lidocaine treatment for chronic pain improve the intensity and duration of pain reduction?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised double-blind crossover study

Primary study design

Interventional

Secondary study design

Randomised cross over trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Signs and Symptoms: Pain

Interventions

1. Lignocaine
2. Non lignocaine

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Change in pain score following treatment.

Secondary outcome measures

Number of patients receiving >50% pain relief, pain relief intensity and sleep interference, duration of pain relief, number and frequency of adverse events, effect on blood pressure.

Overall study start date

01/04/2004

Completion date

31/03/2005

Eligibility**Key inclusion criteria**

20 patients from Pain Management

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

20

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/04/2004

Date of final enrolment

31/03/2005

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

National Hospital for Neurology & Neurosurgery
London
United Kingdom
WC1N 3BG

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Government

Funder Name

University College London Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration